Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study

References

• Gerich JE Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet Med 2010 27 2 136 142 20546255
   PubMed Web of Science ®Google Scholar
• Rahmoune H Thompson PW Ward JM Smith CD Hong G Brown J Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 2005 54 12 3427 3434 16306358
   PubMed Web of Science ®Google Scholar
• Wright EM Loo DD Hirayama BA Biology of human sodium glucose transporters Physiol Rev 2011 91 2 733 794 21527736
   PubMed Web of Science ®Google Scholar
• Brunton SA The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus Int J Clin Pract 2015 69 10 1071 1087 26147213
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 2015 58 3 429 442 25583541
   PubMed Web of Science ®Google Scholar
• Hinnen D Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes Ther Adv Endocrinol Metab 2015 6 3 92 102 26137213
   PubMed Web of Science ®Google Scholar
• Ferrannini E Ramos SJ Salsali A Tang W List JF Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 2010 33 10 2217 2224 20566676
   PubMed Web of Science ®Google Scholar
• Bailey CJ Gross JL Pieters A Bastien A List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 2010 375 9733 2223 2233 20609968
   PubMed Web of Science ®Google Scholar
• Strojek K Yoon KH Hruba V Elze M Langkilde AM Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 2011 13 10 928 938 21672123
   PubMed Web of Science ®Google Scholar
• Jabbour SA Hardy E Sugg J Parikh S Study 10 Group Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study Diabetes Care 2014 37 3 740 750 24144654
   PubMed Web of Science ®Google Scholar
• Wilding JP Woo V Soler NG Pahor A Sugg J Rohwedder K Parikh S Dapagliflozin 006 Study Group Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 2012 156 6 405 415 22431673
   PubMed Web of Science ®Google Scholar
• Nauck MA Del Prato S Meier JJ Durán-García S Rohwedder K Elze M Parikh SJ Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 2011 34 9 2015 2022 21816980
   PubMed Web of Science ®Google Scholar
• Henry RR Murray AV Marmolejo MH Hennicken D Ptaszynska A List JF Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Int J Clin Pract 2012 66 5 446 456 22413962
   PubMed Web of Science ®Google Scholar
• Matthaei S Catrinoiu D Celiński A A randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes Diabetes Care 2015 38 11 2018 2024 26324329
   PubMed Web of Science ®Google Scholar
• Matthaei S Bowering K Rohwedder K Grohl A Parikh S Study 05 Group Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial Diabetes Care 2015 38 3 365 372 25592197
   PubMed Web of Science ®Google Scholar
• Becher H Kostev K Schröder-Bernhardi D Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies Int J Clin Pharmacol Ther 2009 47 10 617 626 19825325
   PubMed Web of Science ®Google Scholar
• Swart E Gothe H Geyer S Jaunzeme J Maier B Grobe TG Ihle P Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations Gesundheitswesen 2015 77 2 120 126 German 25622207
   PubMed Web of Science ®Google Scholar
• Mathieu C Ranetti AE Li D Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes Diabetes Care 2015 38 11 2009 2017 26246458
   PubMed Web of Science ®Google Scholar
• Wilding JP Woo V Rohwedder K Sugg J Parikh S Dapagliflozin 006 Study Group Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years Diabetes Obes Metab 2014 16 2 124 136 23911013
   PubMed Web of Science ®Google Scholar
• Cefalu WT Leiter LA de Bruin TW Gause-Nilsson I Sugg J Parikh SJ Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension Diabetes Care 2015 38 7 1218 1227 25852208
   PubMed Web of Science ®Google Scholar
• Sun YN Zhou Y Chen X Che WS Leung SW The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials BMJ Open 2014 4 4 e004619
   PubMed Web of Science ®Google Scholar
• Goring S Hawkins N Wygant G Roudaut M Townsend R Wood I Barnett AH Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis Diabetes Obes Metab 2014 16 5 433 442 24237939
   PubMed Web of Science ®Google Scholar
• Whaley JM Tirmenstein M Reilly TP Poucher SM Saye J Parikh S List JF Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus Diabetes Metab Syndr Obes 2012 5 135 148 22923998
   PubMedGoogle Scholar
• Grandy S Fox KM Bazata DD Association of self-reported weight change and quality of life, and exercise and weight management behaviors among adults with type 2 diabetes mellitus: the SHIELD study Cardiol Res Pract 2012 2012 892564 22645696
   PubMedGoogle Scholar
• Pi-Sunyer FX The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus Postgrad Med 2009 121 15 94 107 19820278
   PubMed Web of Science ®Google Scholar
• Bolinder J Ljunggren Ö Johansson L Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin Diabetes Obes Metab 2014 16 2 159 169 23906445
   PubMed Web of Science ®Google Scholar
• Baker WL Smyth LR Riche DM Bourret EM Chamberlin KW White WB Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis J Am Soc Hypertens 2014 8 4 262 275 24602971
   PubMed Web of Science ®Google Scholar